Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Ferozsons Laboratories Limited (FEROZ), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | FEROZPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | 39 | 89 | 80 |
| Price and size | |||
| Price | Rs 364.92 | Rs 339.59 | Rs 1,003.93 |
| Today | +0.67% | +0.96% | +0.39% |
| Market cap | Rs 15.9bn | Rs 108.1bn | Rs 98.3bn |
| Traded per day | Rs 4m | Rs 49m | Rs 14m |
| Valuation and dividends | |||
| P/E | 23.1 | 9.9 | 10.6 |
| Dividend yield | 1.6% | 6.1% | 4.4% |
| EPS (last year) | Rs 14.97 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | +23.2% | +53.4% | +52.2% |
| Sales growth | +13.7% | +7.7% | +10.6% |
| Net margin | 4.1% | 15.2% | 10.6% |
| Returns | |||
| 1 month | +9.6% | +8.9% | +7.5% |
| 3 months | −3.0% | −1.6% | +9.4% |
| 1 year | −8.8% | −13.9% | −8.1% |
| vs KSE-100, 1 year | -21.8 pts | -27.0 pts | -21.2 pts |
| Trend and risk | |||
| 52-week position | 40% | 28% | 40% |
| RSI 14 | 59 | 65 | 66 |
| RS rank | 41 | 42 | 64 |
| Volatility | 41% | 34% | 30% |
| Beta | 1.05 | 1.05 | 0.77 |
| danioPSX score | |||
| Value | 16 | 69 | 61 |
| Quality | 60 | 81 | 74 |
| Dividend | 27 | 64 | 34 |
| Momentum | 41 | 40 | 59 |
| Safety | 55 | 80 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener